Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy - 1 Jun 2021

Kawakami Hisato, Ogata Sota

Abstract excerpt

Precision medicine, which considers the genetics of the tumor tissues and cells for selection of the most appropriate treatment strategy, has recently been developed for colorectal cancer. The BRAF mutation status in colorectal cancer has been tested, but precision medicine for BRAF-mutated tumors had not been applicable due to no approved BRAF-targeting drugs until recently. In addition, conventional standard...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cetuximab
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 34139726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].PMID 34139726Read ↗

Current perspectives on the treatment of BRAF mutated colorectal carcinoma.Semantic proximity Read ↗

Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers.Semantic proximity Read ↗

Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer.Semantic proximity Read ↗

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Semantic proximity Read ↗

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.Semantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Semantic proximity Read ↗

A comprehensive overview of the molecular features and therapeutic targets in BRAFV600E-mutant colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.